Accuray Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Employees
  • 809

Employees

  • Stock Symbol
  • ARAY

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.07
  • (As of Friday Closing)

Accuray General Information

Description

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.

Contact Information

Website
www.accuray.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1240 Deming Way
  • Madison, WI 53717-1954
  • United States
+1 (608)
Primary Industry
Other Devices and Supplies
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Corporate Office
  • 1240 Deming Way
  • Madison, WI 53717-1954
  • United States
+1 (608)

Accuray Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Accuray Stock Performance

As of 20-Nov-2026, Accuray’s stock price is $2.07. Its current market cap is $6.22M with 3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.07 $2.12 $2.05 - $45.20 $6.22M 3M 199K -$6.00

Accuray Financials Summary

As of 30-Sep-2026, Accuray has a trailing 12-month revenue of $395M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 175,512 174,999 289,840 327,164
Revenue 394,528 401,947 458,505 446,551
EBITDA 28,906 (7,220) 19,046 4,478
Net Income (17,382) (49,194) (1,591) (15,545)
Total Assets 390,055 443,676 470,239 468,627
Total Debt 135,974 183,874 176,377 210,747
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Accuray Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Accuray‘s full profile, request access.

Request a free trial

Accuray Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions
Other Devices and Supplies
Madison, WI
809 As of 2026

Gosselies, Belgium
 

Gieres, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Accuray Competitors (17)

One of Accuray’s 17 competitors is OncoDNA, a Venture Capital-Backed company based in Gosselies, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OncoDNA Venture Capital-Backed Gosselies, Belgium
eCential Robotics Venture Capital-Backed Gieres, France
Varian Medical Systems Venture Capital-Backed Palo Alto, CA
ZAP Surgical Venture Capital-Backed San Carlos, CA
ViewRay Formerly VC-backed Bedford, OH
You’re viewing 5 of 17 competitors. Get the full list »

Accuray Patents

Accuray Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026035438-A1 Dynamic volume registration for image-guided radiotherapy Pending 09-Aug-2024
WO-2026015276-A1 Efficient medical dataset presentation Pending 10-Jul-2024
WO-2026006077-A1 Apparatus and method of generating beam control data based on imaging uncertainty Pending 28-Jun-2024
WO-2026006082-A1 Apparatus and method of image deformation based on imaging uncertainty Pending 28-Jun-2024
JP-2024156622-A Fundamental of semi-conductor-based photon counting detector Pending 24-Apr-2023 A61B6/44
To view Accuray’s complete patent history, request access »

Accuray Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Accuray Investments & Acquisitions (4)

Accuray’s most recent deal was a Joint Venture with CNNC Accuray (Tianjin) Medical Technology. The deal was made on 28-Jan-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CNNC Accuray (Tianjin) Medical Technology 28-Jan-2019 Joint Venture Therapeutic Devices
Morphormics 16-Jul-2012 Merger/Acquisition Other Healthcare Technology Systems
Compact Particle Acceleration 16-May-2012 Early Stage VC Therapeutic Devices
TomoTherapy 13-Jun-2011 Merger/Acquisition Therapeutic Devices
To view Accuray’s complete investments and acquisitions history, request access »

Accuray ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.01 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view Accuray’s complete esg history, request access »

Accuray Exits (1)

Accuray’s most recent exit was on 16-May-2012 from Compact Particle Acceleration. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Compact Particle Acceleration 16-May-2012 Completed
  • 4 buyers
To view Accuray’s complete exits history, request access »

Accuray FAQs

  • When was Accuray founded?

    Accuray was founded in 1990.

  • Where is Accuray headquartered?

    Accuray is headquartered in Madison, WI.

  • What is the size of Accuray?

    Accuray has 809 total employees.

  • What industry is Accuray in?

    Accuray’s primary industry is Other Devices and Supplies.

  • Is Accuray a private or public company?

    Accuray is a Public company.

  • What is Accuray’s stock symbol?

    The ticker symbol for Accuray is ARAY.

  • What is the current stock price of Accuray?

    As of 20-Nov-2026 the stock price of Accuray is $2.07.

  • What is the current market cap of Accuray?

    The current market capitalization of Accuray is $6.22M.

  • What is Accuray’s current revenue?

    The trailing twelve month revenue for Accuray is $395M.

  • Who are Accuray’s competitors?

    OncoDNA, eCential Robotics, Varian Medical Systems, ZAP Surgical, and ViewRay are some of the 17 competitors of Accuray.

  • What is Accuray’s annual earnings per share (EPS)?

    Accuray’s EPS for 12 months was -$6.00.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process